lecanemab – Medxy AI

Dynamic Plasma Biomarkers Reveal Multifaceted Effects of Lecanemab in Early Alzheimer’s Disease

By MedXY 09/29/2026

This longitudinal study investigates plasma biomarker dynamics in Alzheimer's patients treated with lecanemab, revealing distinct biomarker trajectories that reflect amyloid clearance, tau modulation, and immune responses, offering insights into treatment monitoring and prognostication.

Neurology Specialties

FDA Approves Subcutaneous Lecanemab for Maintenance Treatment in Early Alzheimer’s Disease: A Step Toward More Accessible Care

By MedXY 09/02/2025

The FDA has approved a subcutaneous form of lecanemab for maintenance therapy in early Alzheimer’s, offering similar clinical benefits to IV dosing with improved convenience and safety, potentially transforming patient care delivery.

Clinical Updates Medical News Neurology Specialties

Lecanemab in Community Practice: Real-World Safety and Efficacy for Early Alzheimer’s Disease

By MedXY 07/29/2025

Community-based data suggest lecanemab is safe and effective for early-stage Alzheimer’s, with manageable ARIA rates and infusion reactions, particularly in ApoE4 noncarriers.